Thursday 7 May, 2026
Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with an estimated 103,727 new cases reported globally in…
Read moreAbstracts
Modeling Treatment Response to Secukinumab in Psoriasis Using Machine Learning and Time-to-Event Modeling
Thursday 7 May, 2026
Introduction Secukinumab, an interleukin-17A inhibitor, is an established therapy for moderate-to-severe plaque psoriasis, but wide interindividual variability in response is…
Read moreTOWARD PRECISION DOSING OF CEFTRIAXONE IN CHILDREN WITH SICKLE CELL DISEASE
Thursday 7 May, 2026
Introduction: Infections are the leading cause of mortality among patients with sickle cell disease (SCD) worldwide. [1] This population is…
Read moreNext-Generation Pharmacometric Modeling Using Variational Autoencoders
Thursday 7 May, 2026
Objectives Accurate pharmacometrics (PMX) modeling is essential for optimizing drug therapy and understand-ing patient variability. Nonlinear mixed-effect (NLME) models are…
Read moreUSE OF VIRTUAL TWINS TO ESTABLISH A PREDICTIVE MODEL BETWEEN SIMULATED IL-6 CONCENTRATIONS AND CRS RISK DURING ODRONEXTAMAB STEP-UP DOSING IN B-CELL LYMPHOMA PATIENTS
Thursday 7 May, 2026
Introduction: Excessive cytokine release following administration of T-cell engagers can trigger life-threatening cytokine-release syndrome (CRS) adverse events. Severe CRS symptoms…
Read moreCROSS-PLATFORM REPRODUCIBILITY OF POPULATION PHARMACOKINETIC MODELING: TRANSLATION FROM NONMEM TO PUMAS
Thursday 7 May, 2026
Objectives Population pharmacokinetic (PopPK) modeling plays a central role in model-informed drug development (MIDD); supporting decision-making throughout clinical development and…
Read moreA lesion-centric extension of a minimal PBPK model to predict anti-tuberculosis drug target attainment in rabbits
Thursday 7 May, 2026
Objectives: Tuberculosis (TB), one of the deadliest infectious diseases worldwide [1], still requires therapy optimization to eradicate Mycobacterium tuberculosis residing…
Read moreAutomating Scalable End-to-End MIDD Workflows: A Database-Driven Framework for Modular PBPK-QSP Assembly using the Open Systems Pharmacology Suite
Thursday 7 May, 2026
Objective Current modelling workflows in pharmacometrics and systems pharmacology rely heavily on manual steps, particularly when assembling standard model structures…
Read moreDolutegravir dose optimization based on population pharmacokinetics and pharmacogenetics in Thai people living with HIV
Thursday 7 May, 2026
Objectives: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor, is currently recommended as a first-line treatment for people living with…
Read moreA pharmacometric model of the in vitro co-dynamics of Staphylococcus aureus and three phage candidates
Thursday 7 May, 2026
Objectives Phage therapy is a promising approach for treating infections caused by multidrug-resistant bacteria such as Staphylococcus aureus (S. aureus)….
Read more